Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients

Sputum Type 2 markers could predict remission in severe asthma treated with anti-Interleukin-5.

(2023) C. Moermans et al.   CHEST

Factors associated with suboptimal response to monoclonal antibodies in severe asthma

(2023) Luis Pérez de Llano et al.   ALLERGY

Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study

(2023) Ian Pavord et al.   Frontiers in Immunology

Response to biologics and clinical remission in the adult GAN severe asthma registry cohort

(2023) Katrin Milger et al.   Journal of Allergy and Clinical Immunology-In Practice

A Real-World Study of Achievement Rate and Predictive Factors of Clinical and Deep Remission to Biologics in Patients with Severe Asthma

(2023) Keiji Oishi et al.   Journal of Clinical Medicine

Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab

(2022) Andrew Menzies-Gow et al.   ADVANCES IN THERAPY

Asthma remission- what is it and how can it be achieved?

(2022) Dennis Thomas et al.   EUROPEAN RESPIRATORY JOURNAL

Treatable traits in asthma: moving beyond diagnostic labels

(2022) Vanessa M McDonald et al.   MEDICAL JOURNAL OF AUSTRALIA

Long-Term Efficacy and Clinical Remission After Benralizumab Treatment in Patients with Severe Eosinophilic Asthma: A Retrospective Study

(2022) Takanori Numata et al.   Journal of Asthma and Allergy

Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab Registry

(2021) Dennis Thomas et al.   Journal of Allergy and Clinical Immunology-In Practice

2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

(2021) Liana Fraenkel et al.   Arthritis & Rheumatology

ERS/ATS technical standard on interpretive strategies for routine lung function tests

(2021) Sanja Stanojevic et al.   EUROPEAN RESPIRATORY JOURNAL

Mepolizumab effectiveness and identification of super-responders in severe asthma

(2020) Erin S. Harvey et al.   EUROPEAN RESPIRATORY JOURNAL

The Relationship of Asthma Biologics to Remission for Asthma

(2020) Andrew Menzies-Gow et al.   Journal of Allergy and Clinical Immunology-In Practice

Rate of normal lung function decline in ageing adults: a systematic review of prospective cohort studies

(2019) Elizabeth T Thomas et al.   BMJ Open

Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma

(2019) William W. Busse et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

An expert consensus framework for asthma remission as a treatment goal

(2019) Andrew Menzies-Gow et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial

(2017) Peter G Gibson et al.   LANCET

Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma

(2017) Parameswaran Nair et al.   NEW ENGLAND JOURNAL OF MEDICINE

Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria

(2016) M. Hew et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry

(2016) P. G. Gibson et al.   INTERNAL MEDICINE JOURNAL

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

(2016) J Mark FitzGerald et al.   LANCET

Remission of asthma: The next therapeutic frontier?

(2011) John W. Upham et al.   PHARMACOLOGY & THERAPEUTICS